| Antiretroviral therapy, n (%)(1) | (n = 279) |
| NNRTI-based, n = 151 (54) |
|
| Efavirenz (EFV) 600 mg (qd) + zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) | 78 (52) |
| Efavirenz (EFV) 600 mg (qd) + estavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) | 11 (7) |
| Efavirenz (EFV) 600 mg (qd) + tenofovir (TDF) 300 mg + lamivudine (3TC) 150 mg (bid) | 8 (5) |
| Nevirapine (NVP) 200 mg (bid) + zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) | 28 (19) |
| Nevirapine (NVP) 200 mg (bid) + estavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) | 15 (10) |
| Nevirapine (NVP) 200 mg (bid) + tenofovir (TDF) 300 mg + lamivudine (3TC) 150 mg (bid) | 11 (7) |
| PI-based, n = 128 (46) |
|
| Lopinavir/ritonavir (LOP/r) 400 mg/100 mg (bid) + zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) | 60 (46) |
| Lopinavir/ritonavir (LOP/r) 400 mg/100 mg (bid) + estavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) | 68 (54) |